A substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy

Population characteristics and survival in 127 referred cats with hypertrophic cardiomyopathy (1997 to 2005)

OBJECTIVES

To evaluate the characteristics and survival of a recent population of cats with hypertrophic cardiomyopathy.

METHODS

Records at the Royal Veterinary College Queen Mother Hospital for Animals were searched for cats diagnosed with hypertrophic cardiomyopathy between 1997 and 2005. Referring veterinarians and owners were contacted to determine survival times.

RESULTS

Cats with hypertrophic cardiomyopathy were evaluated for population characteristics (n=127) and survival times (n=109). Overall median survival from date of hypertrophic cardiomyopathy diagnosis at the Queen Mother Hospital for Animals was 1276 days. Cats with hypertrophic cardiomyopathy were younger (P=0·009), and more likely to be male (P<0·001) compared to a hospital control group (n=1473), and Ragdolls were over-represented (P<0·05). Characteristics associated with increased survival in univariate analysis included younger age (P=0·007), asymptomatic status (P<0·001), normal left atrial size (P<0·001) and presence of systolic anterior motion of the mitral valve (P=0·003). Systolic anterior motion was associated with asymptomatic status, and did not influence survival in asymptomatic cats or those in congestive heart failure. Age, left atrial size and breed were significantly associated with survival time in a multivariate analysis.

CLINICAL SIGNIFICANCE

Cats with hypertrophic cardiomyopathy and left atrial enlargement have a poorer prognosis. The positive influence of systolic anterior motion on survival is likely to be linked to its association with asymptomatic status.

Comparison of auscultatory and echocardiographic findings in healthy adult cats

OBJECTIVES

This pilot study was performed to investigate murmur prevalence and to explore the association between auscultatory and echocardiographic findings in apparently healthy cats in order to design a larger study.

ANIMALS, MATERIALS AND METHODS

Adult cats in 4 rehoming centres were screened by auscultation and echocardiography (echo) over 2 periods of 2 weeks each. In the first period, echo was attempted only in cats with murmurs. In the second period, all cats underwent auscultation by 2 observers and echo. LVH was defined in 5 ways: maximal diastolic left ventricular (LV) wall thickness ≥ 6 mm or ≥ 5.5 mm with 2D (LVH(6 2D), LVH(5.5 2D), respectively) or M-Mode echo (LVH(6 MM) or LVH(5.5 MM) respectively), or LV wall thickness ≥ 6 mm (2D) for >50% of a wall segment (LVH(50%)).

RESULTS

67/199 (34%) cats had a murmur. Interobserver agreement on murmur presence was moderate (κ 0.47). 61 cats with a murmur and 31 cats without underwent both auscultation and echo. Depending on the criteria, LVH was present in 31 (LVH(6 2D)), 21 (LVH(50%)) and 11 (LVH(6 MM)) scanned cats. 18-62% of cats with murmurs had LVH, depending on the echo criteria used. Agreement was best between observers in identifying LVH using LVH(6 2D) and LVH(50%) (κ = 1.0).

CONCLUSIONS

Heart murmurs are common in apparently healthy cats. The prevalence of LVH varies depending on the criteria used.

Feline genetics: clinical applications and genetic testing

DNA testing for domestic cat diseases and appearance traits is a rapidly growing asset for veterinary medicine. Approximately 33 genes contain 50 mutations that cause feline health problems or alterations in the cat's appearance. A variety of commercial laboratories can now perform cat genetic diagnostics, allowing both the veterinary clinician and the private owner to obtain DNA test results. DNA is easily obtained from a cat via a buccal swab with a standard cotton bud or cytological brush, allowing DNA samples to be easily sent to any laboratory in the world. The DNA test results identify carriers of the traits, predict the incidence of traits from breeding programs, and influence medical prognoses and treatments. An overall goal of identifying these genetic mutations is the correction of the defect via gene therapies and designer drug therapies. Thus, genetic testing is an effective preventative medicine and a potential ultimate cure. However, genetic diagnostic tests may still be novel for many veterinary practitioners and their application in the clinical setting needs to have the same scrutiny as any other diagnostic procedure. This article will review the genetic tests for the domestic cat, potential sources of error for genetic testing, and the pros and cons of DNA results in veterinary medicine. Highlighted are genetic tests specific to the individual cat, which are a part of the cat's internal genome.

NT-proBNP measurement fails to reliably identify subclinical hypertrophic cardiomyopathy in Maine Coon cats

The purpose of this study was to evaluate the value of measuring plasma NT-proBNP concentration as a screening tool in cats with varying severity of subclinical hypertrophic cardiomyopathy (HCM). Plasma NT-proBNP concentration was measured in 35 cats that had previously been classified as normal, equivocal, moderate HCM or severe HCM via echocardiography. No cat had ever been in congestive heart failure. Cats with severe HCM had a significantly higher NT-proBNP concentration compared to the other groups (P<0.0003), however, the sensitivity of NT-proBNP for diagnosing cats with severe disease was only 44% (cutoff≤100pmol/l) to 55% (cutoff≤40pmol/l). There was no significant difference in NT-proBNP concentration between normal, equivocal and moderate categories (sensitivity for detecting moderate HCM was 0%). Based on the results of this study, NT-proBNP concentration is not considered adequate as a screening test for detecting mild to moderate HCM in Maine Coon cats and it appears that it may miss many cats with severe HCM.

Association of A31P and A74T polymorphisms in the myosin binding protein C3 gene and hypertrophic cardiomyopathy in Maine Coon and other breed cats

BACKGROUND

Hypertrophic cardiomyopathy (HCM) is an inherited autosomal dominant trait in cats. The A31P single nucleotide polymorphism (SNP) in the myosin binding protein C 3 gene is thought to be the causative mutation in Maine Coon cats. Additionally, the A74T SNP is offered as a genetic test for HCM.

OBJECTIVES

To evaluate the genetic association between the above-mentioned SNPs and phenotypes.

ANIMALS

Eighty-three Maine Coon cats and 68 cats of other breeds.

METHODS

The study was performed prospectively. Cats were phenotyped as healthy or HCM with echocardiography. Taqman genotyping assays were used for genotyping; results were confirmed by sequencing analysis.

RESULTS

A31P was found in 18/83 (22%) Maine Coon cats. Fifteen of 18 Maine Coons (83%) with the A31P mutation were healthy on echocardiographic examination (mean age 65 months). A74T was present in 28/79 (35%) of Maine Coons and in 42/68 (62%) of other cat breeds. Twenty-two of 28 (79%) of Maine Coons and 21/42 (62%) of other breed cats with the A74T mutation were healthy at a mean age of 72 months and 91 months, respectively. Of 12 Maine Coons with HCM, 9 (75%) were genotype-negative for A31P and 6 (50%) for A74T. Allele frequencies did not differ significantly (P= .47) between phenotype groups. None of the evaluated genetic tests was able to provide useful predictive information of disease outcome.

CONCLUSIONS AND CLINICAL IMPORTANCE

The value of currently available genetic tests is low in the cats of this study. The mutations analyzed appear to have a low penetrance, and even homozygote cats can remain healthy.

Echocardiographic assessment of left ventricular geometry and the mitral valve apparatus in cats with hypertrophic cardiomyopathy

OBJECTIVES

This retrospective study addressed the general hypothesis that abnormalities of the mitral valve apparatus are common in cats with idiopathic hypertrophic cardiomyopathy (HCM) and contribute to dynamic obstruction of the left ventricular outflow tract (LVOT).

ANIMALS, MATERIALS AND METHODS

106 cats (28 controls and 78 with HCM) had transthoracic two-dimensional and Doppler echocardiography performed with quantification of 33 variables. Three groups of cats (control [Group-1], HCM without obstruction [Group-2], and HCM with obstruction [Group-3]) were identified and compared by analysis of variance, chi(2) analysis, and correlation analysis.

RESULTS

Cats in Group-3 had more LV and papillary muscle hypertrophy, increased length of the anterior mitral valve leaflet, and a higher prevalence of false tendons in the LVOT compared to cats in Group-2 (P < or = 0.05). The length of the anterior mitral valve leaflet was correlated to the severity of dynamic obstruction (P < or = 0.05) and the magnitude of LV hypertrophy (P < or = 0.001). Systolic anterior motion of chordae tendineae (CAM) was observed in 16% of control cats and >50% of cats with HCM (P < or = 0.05).

CONCLUSIONS

Abnormalities of the mitral valve are common in cats with HCM suggesting a possible role in the pathogenesis of dynamic outflow tract obstruction.

Hypertrophic Cardiomyopathy in Two Captive Bennett's Wallabies (Macropus Rufogriseus Rufogriseus)

Hypertrophic cardiomyopathy (HCM) was diagnosed during postmortem examination of 2 captive adult Bennett's wallabies ( Macropus rufogriseus rufogriseus). The wallabies were members of a mob (herd) of 3 wallabies, and 2 died spontaneously without clinical signs of heart failure being detected. Gross lesions in both cases included marked concentric hypertrophy of the left ventricle, pulmonary edema, and multifocal hemorrhage and subcutaneous edema of the hind limbs. Histologic lesions of the heart were limited to mild cardiac myofiber disarray and marked cardiac myofiber hypertrophy. A specific etiology for the HCM was not determined in either animal. The cardiac changes are similar to the left ventricular hypertrophy previously described in kangaroos.

Feline myocardial disease 2: diagnosis, prognosis and clinical management

Clinical challenges The diagnosis, prognosis and clinical management of feline myocardial disease (cardiomyopathy, CM) represent controversial areas in veterinaty cardiology. Diagnosis is challenging primarily because of the complex classification of feline CM, which is based on a variety of structural and functional phenotypes. Similarly, prognosis is strongly dependent on the underlying aetiology and stage of the disease, which are often unrecognised. These challenges underline the importance of a thonaugh clinical evaluation of the patient and understanding of the underlying pathophysiological mechanisms in order to select the most appropriate treatment and provide the highest standards of care.

Patient group Although a genetic predisposition has been demonstrated in some feline pedigrees (ie, Maine Coons, Ragdolls), CM can potentially affect all breeds and different age groups.

Audience General practitioners, as well as specialists in small animal medicine, cardiology and pathology, deal with feline CM cases on a regular basis.

Diagnostics Diagnosis of feline CM is primarily based on echocardiographic examination. However, even the most sophisticated techniques present important limitations because they do not necessarily identify the primary cause of the disease or recognise the precise origin of an end-stage myocardial disease. Thoracic radiography remains one of the most useful tools for identifying changes consistent with congestive heart failure. Novel diagnostic techniques include cardiac magnetic resonance imaging, positron emission tomography and genetic tests.

Evidence base Although knowledge of feline CM remains fairly rudimentary, important discoveries have been made in the past few years. Evidence-based studies have significantly improved understanding of genetic predisposition, biomarkers and response to pharmacological treatments. Hopefully, many of the unsolved questions raised in this article will find a definitive answer in the near future.

Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy

OBJECTIVE

To evaluate the utility of feline NT-proBNP plasma concentration [NT-proBNP] as a screening tool for cats with subclinical hypertrophic cardiomyopathy (HCM).

ANIMALS, MATERIALS AND METHODS

Forty adult Maine Coon or Maine Coon crossbred cats from the feline HCM research colony at the University of California, Davis were studied. All cats had previously been genotyped as heterozygous or negative for the A31P myosin binding protein C (MYBPC) mutation. Echocardiograms were performed to assess the severity of HCM in each cat. Blood samples were collected for evaluation of [NT-proBNP].

RESULTS

In these cats with severe HCM, [NT-proBNP] was significantly elevated (P<0.0001) when compared to all other groups of cats and an [NT-proBNP]>44pmol/L accurately predicted the presence of severe HCM. However, [NT-proBNP] was not increased in cats with moderate or equivocal HCM when compared to normal cats. Cats heterozygous for the MYBPC mutation had a significantly elevated [NT-proBNP] when compared to cats without the A31P mutation (P=0.028).

CONCLUSIONS

Measurement of [NT-proBNP] has a high sensitivity and specificity as a means of detecting severe HCM in cats, but it is not sensitive for the identification of moderate HCM as judged by the evaluation of Maine Coon and Maine Coon cross cats in our colony. Consequently, we conclude that this test cannot be used to screen cats for the presence of mild to moderate HCM.

Comparisons of morphometric measurements and serum insulin-like growth factor concentration in healthy cats and cats with hypertrophic cardiomyopathy

OBJECTIVE

To compare morphometric measurements and serum insulin-like growth factor (IGF-1) concentration in cats with and without hypertrophic cardiomyopathy (HCM), and assess the hypothesis that cats with HCM have larger body size and skeletal features and higher serum IGF-1 concentrations than healthy cats.

ANIMALS

25 cats with HCM and 22 healthy control cats.

PROCEDURES

Physical examination and echocardiography were performed to classify cats into the HCM and control groups. Data collected from each cat included diet history, body weight, body condition score, lengths of the humerus and 4th and 12th thoracic vertebrae, heart size, head length and width, and abdominal circumferences. Comparisons of these variables were made between groups.

RESULTS

Body condition score in HCM-affected and control cats did not differ significantly. However, median head width; lengths of the head, 4th and 12th thoracic vertebrae, and humerus; and body weight in the HCM-affected group were significantly greater than values in the control group. Median serum concentration of IGF-1 was not significantly different between groups.

CONCLUSIONS AND CLINICAL RELEVANCE

These data suggested that among the study cats, those with HCM were skeletally larger, but not more obese, than healthy cats. Whether this was attributable to differences in early growth or other causes requires additional investigation.